Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Glossary of Hostile Takeover Terms with Discussion
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 5135581"]<b>July 1st updates</b></p><p><br /></p><p>In the interview, Allergan CEO Pyott was more specific. Pyott has met with investors to talk about the company's defense, which he said could include issuing new debt to buy back shares. He said Allergan could borrow up to $10 billion without affecting its investment-grade rating, but he did not say how much the company might spend on the buybacks.</p><p><br /></p><p>"Our goal now is to give them most of what they want," Pyott said, referring to Allergan shareholders.</p><p><br /></p><p>A leveraged buyback would increase the amount of Allergan's debt, making its balance sheet less attractive to a would-be acquirer. Allergan currently has little debt, one of the company features that appeals to debt-laden Valeant.</p><p><br /></p><p>A buyback would also reduce the number of shares outstanding, which would raise its earnings per share and increase shareholder value. An acquisition by Allergan could also increase earnings, he said.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 5135581"][b]July 1st updates[/b] In the interview, Allergan CEO Pyott was more specific. Pyott has met with investors to talk about the company's defense, which he said could include issuing new debt to buy back shares. He said Allergan could borrow up to $10 billion without affecting its investment-grade rating, but he did not say how much the company might spend on the buybacks. "Our goal now is to give them most of what they want," Pyott said, referring to Allergan shareholders. A leveraged buyback would increase the amount of Allergan's debt, making its balance sheet less attractive to a would-be acquirer. Allergan currently has little debt, one of the company features that appeals to debt-laden Valeant. A buyback would also reduce the number of shares outstanding, which would raise its earnings per share and increase shareholder value. An acquisition by Allergan could also increase earnings, he said.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Glossary of Hostile Takeover Terms with Discussion
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Glossary of Hostile Takeover Terms with Discussion
>